11 th Best of ASCO Lebanon
|
|
- Ross Goodwin
- 5 years ago
- Views:
Transcription
1
2 11 th Best of ASCO Lebanon September 2-3, Phoenicia Hotel, Beirut - Lebanon Organized by LSMO Sponsored by ASCO Co- Joseph Makdessi, MD Nagi El Saghir, MD Planning Committee: Adnan Atallah, MD - Nizar Bitar, MD - Nagi El Saghir, MD - Oussama Jradi, MD Joseph Makdessi, MD - Arafat Tfayli, MD Invited Guest Ghassan Abou-Alpha, MD Sana Al-Sukhun, MD Ahmad Awada, MD Hamdy A. Azim, MD Showki Bazarbachi, MD Tony Choueiri, MD Nuhad Ibrahim, MD Mohamad Jaloudi, MD Fadlo R. Khuri, MD Eileen O Reilly, MD Mohamad Mohty, MD Memorial Sloan Kettering Cancer Center University of Jordan Institut Jules Bordet Cairo University King Faisal Specialist Hospital Dana Farber Cancer Institute MD Anderson Cancer Center Tawwam Hospital American University of Beirut Memorial Sloan Kettering Cancer Center Hopital Saint-Antoine, Paris, France
3 Friday 2 nd of September :00 Registration 09:00-11:00 Lung Cancer-Non-Small Cell Metastatic / Small Cell / Head Neck Developmental therapeutics Fadlo Khuri, MD - Arafat Tfayli, MD - Fadi Karak, MD Fady Geara, MD - Salim Shammas, MD - Francois Kamar, MD Hazem Assi, MD 09:00-09:40 Part 1: Systemic Agents - Lung Abstract 108: Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). Alexander E. Drilon, MD Presented by Fadlo Khuri, MD Abstract 9008: Primary analysis for alectinib versus crizotinib in ALK-inhibitor naïve ALK positive non-small cell lung cancer (ALK+ NSCLC) in randomized openlabel phase III trial (J-ALEX study). Hiroshi Nokihara, MD Presented by Fadlo Khuri, MD Abstract 9012: A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): LURET study. Takashi Seto, MD Presented by Hazem Assi, MD Abstract LBA8505: Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). Charles M. Rudin, MD Presented by Fadi Karak, MD
4 Friday 2 nd of September :40-10:00 Part 2: Head and Neck Abstract 6000: Induction docetaxel platinum 5-FU (TPF) followed by cetuximabradiotherapy (cetux-rt) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC phase III randomized trial. Lionnel Geoffrois, MD Presented by Arafat Tfayli, MD Abstract 6007: Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial. Li Zhang, MD Presented by Arafat Tfayli, MD 10:00-10:10 Part 3: Brain Abstract LBA2: A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC , TROG 08.02, NCT ). James R. Perry, MD Presented by Francois Kamar, MD 10:10-10:50 Part 4: Immunotherapy Abstract 6009: Nivolumab versus therapy of investigator s choice (IC) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. Robert L. Ferris, MD Presented by Fadlo Khuri, MD 30-12:00 Coffee Break Abstract 6011: Preliminary results from KEYNOTE-055: pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). Joshua Bauml, MD Presented by Fadlo Khuri, MD Abstract 100: CheckMate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). Scott Joseph Antonia, MD Presented by Fadi Karak, MD
5 Friday 2 nd of September 2016 Abstract 3001: CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. Matthew David Hellmann, MD Presented by Arafat Tfayli, MD 10:00-11:10 Part 5: Radiation Therapy Abstract 9004: Local Consolidative Therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study. Daniel Richard Gomez, MD Presented by Fadi Geara, MD Abstract 8500: Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. Zhongxing X. Liao, MD Presented by Fadi Geara, MD Abstract 8504: CONVERT: An international randomised controlled trial of concurrent chemo-radiotherapy (cctrt) comparing twice-daily (BD) and once-daily (OD) radiotherapy (RT) schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS) (NCT ). Corinne Faivre-Finn, MD Presented by Selim Chamas, MD 11:10-11:30 Coffee Break
6 Friday 2 nd of September :30-12:30 Gastrointestinal (Colorectal) Cancer Ghassan Abou-Alfa, MD - Ali Shamseddine, MD Shawki Bazarbachi, MD Abstract 3503: NCI9673: A Multi-Institutional ETCTN Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA). Van Karlyle Morris II, MD Presented by Ali Shamseddine, MD Abstract 3504: Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mcrc): Analysis of CALGB/SWOG (Alliance). Alan P. Venook, MD Presented by Ghassan Abou-Alfa, MD Abstract 3507: CREST: Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer Results of the UK ColoRectal Endoscopic Stenting Trial (CREST). James Hill, MD Presented by Ali Shamseddine, MD Abstract 3511: The potential of circulating tumor DNA (ctdna) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. Jeanne Tie, MD Presented by Ghassan Abou-Alfa, MD Abstract 3512: FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized study - Prodige 14 Accord 21 (METHEP-2), a UNICANCER GI trial. Marc Ychou, MD Presented by Shawki Bazarbachi, MD 12:30-13:00 Educational Session: Genomic and Genetic Testing in Oncology Hamdy Abdel Azim, MD - Nagi El Saghir, MD 13:00-14:00 Lunch Break
7 Friday 2 nd of September :00-15:00 Gastrointestinal (Noncolorectal) Cancer Eileen O Reilly, MD - Ghassan Abou-Alfa, MD Abstract 4000: A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. Marcel Verheij, MD Presented by Eileen O Reilly, MD Abstract LBA4001: FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a firstin-class anti-cldn18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Salah-Eddin Al-Batran, MD Presented by Eileen O Reilly, MD Abstract 4003: Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB (Alliance). Ghassan K. Abou-Alfa, MD Presented by Ghassan Abou-Alfa, MD Abstract 4005: NETTER-1 Phase III: Efficacy and Safety Results in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate. Jonathan R. Strosberg, MD Presented by Eileen O Reilly, MD Abstract LBA4006: ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. John P. Neoptolemos, MD Presented by Eileen O Reilly, MD 11:30-12:00 Coffee Break
8 Friday 2 nd of September :00-15:45 Hematologic Malignancies Lymphoma & Chronic Lymphocytic Leukemia Hamdy Abdel Azim, MD - Ali Bazerbachi, MD Nizar Bitar, MD - Jean El Cheikh, MD - Jawad Makarem, MD Abstract 7501: A prospective, multicenter, randomized study of anti-ccr4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult t-cell leukemialymphoma (ATL). Adrienne Alise Phillips, MD Presented by Ali Bazerbachi, MD Abstract 7503: Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase 2 study (a subgroup study of the StiL NHL MAINTAIN trial). Mathias J. Rummel, MD Presented by Jawad Makarem, MD Abstract 7504: Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study. Pieternella J. Lugtenburg, MD Presented by Nizar Bitar, MD Abstract 7506: PILLAR-2: A randomized, double-blind, placebo-controlled, phase 3 study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). Thomas E. Witzig, MD Presented by Hamdy Abdel Azim, MD Abstract 7508: A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma. Steven I. Park, MD Presented by Jean El Cheikh, MD 15:45-16:00 Coffee Break
9 Friday 2 nd of September :00-16:30 Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, & Allotransplant Ziad Salem, MD - Nabil Chamseddine, MD Ahmad Ibrahim, MD Abstract 7000: Phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. Jeffrey E. Lancet, MD Presented by Ziad Salem, MD Abstract 7001: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTfreedom study. Andreas Hochhaus, MD Presented by Nabil Chamseddine, MD Abstract 7008: Crenolanib besylate, a type I pan-flt3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. Jorge E. Cortes, MD Presented by Ahmad Ibrahim, MD Abstract 7009: Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients 65 years ineligible for standard induction therapy. Daniel Aaron Pollyea, MD Presented by Ahmad Ibrahim, MD 11:30-12:00 Coffee Break
10 Friday 2 nd of September :30-17:00 Hematologic Malignancies - Plasma Cell Dyscrasia Mohamad Mohty, MD Abstract 8000: Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM Trial). Michele Cavo, MD Presented by Mohamad Mohty, MD Abstract 8001: Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). Michel Attal, MD Presented by Mohamad Mohty, MD Abstract 8003: Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients. Sham Mailankody, MD Presented by Mohamad Mohty, MD Abstract LBA4: Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. Antonio Palumbo, MD Presented by Mohamad Mohty, MD 17:00-17:30 Opening Ceremony 20:00 Gala Dinner 15:45-16:00 Coffee Break 11:30-12:00 Coffee Break
11 Saturday 3 rd of September :00 Registration 09:00-09:45 Breast Cancer - Triple-Negative / Cytotoxic Chemotherapy / Local Therapy Nuhad Ibrahim, MD - Hamdy Abdel Azim, MD - Jaber Abbas, MD Abstract 1000: Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR , NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/ taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2- negative breast cancer. Atilla Soran, MD Presented by Nuhad Ibrahim, MD Abstract 1005: A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). Ravi Vij, MD Presented by Hamdy Abdel Azim, MD Abstract 1007: Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance). Armando E. Giuliano, MD Presented by Jaber Abbas, MD
12 Saturday 3 rd of September :45-10:45 Breast Cancer - HER2/ER+ Sana Al-Sukhun, MD - Nuhad Ibrahim, MD - Nagi El-Saghir, MD Abstract LBA1: A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. Paul E. Goss, MD Presented by Sana Al-Sukhun, MD Abstract 500: Pathologic complete response rates after neoadjuvant trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + trastuzumab + pertuzumab treatment in patients with HER2-positive early breast cancer (KRISTINE). Sara A. Hurvitz, MD Presented by Nuhad Ibrahim, MD Abstract LBA503: Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O vs Herceptin. Hope S. Rugo, MD Presented by Nuhad Ibrahim, MD Abstract 507: PALOMA-2: Primary results from a phase 3 trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2 advanced breast cancer (ABC). Richard S. Finn, MD Presented by Nagi El-Saghir, MD Abstract 512: Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctdna). Nicholas C. Turner, MD Presented by Nagi El-Saghir, MD 11:00-11:30 Coffee Break
13 Saturday 3 rd of September :30-12:00 Gynecologic Cancer Muhieddine Seoud, MD Abstract 5501: Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. Jonathan A. Ledermann, MD Presented by Muhieddine Seoud, MD Abstract LBA5503: OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). Helen Mackay, MD Presented by Muhieddine Seoud, MD Abstract 5507: Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS. Usha Menon, MD Presented by Muhieddine Seoud, MD
14 Saturday 3 rd of September :00-13:00 Melanoma / Skin Cancers Ahmad Awada, MD - Hazem Assi, MD Abstract 9502: Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Keith T. Flaherty, MD Presented by Ahmad Awada, MD Abstract 9503: 3-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Caroline Robert, MD Presented by Ahmad Awada, MD Abstract 9504: Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. Jacob Schachter, MD Presented by Hazem Assi, MD Abstract 9505: Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Jedd D. Wolchok, MD Presented by Ahmad Awada, MD Abstract 9506: Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. Georgina V. Long, MD Presented by Ahmad Awada, MD 13:00-14:00 Lunch Break
15 Saturday 3 rd of September :00-14:30 Educational session: What s Next in Cancer Immunotherapy Speaker: Ahmad Awada, MD 14:30-14:45 Patient and Survivor Care Mohamad Jaloudi, MD Abstract 10019: Placebo-controlled phase III study comparing dexamethasone on day1 to on day1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy. Kunihiro Matsuzaki, MD Presented by Mohamad Jaloudi, MD 14:45-15:45 Genitourinary (Prostate) Cancer Tony Choueiri, MD - Joseph Kattan, MD - Elie Nasr, MD Abstract 5001: A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12. Goran Ahlgren, MD Presented by Joseph Kattan, MD Abstract 5004: Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805). Linda J. Patrick-Miller, MD Presented by Tony Choueiri, MD Abstract 5006: Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mcrpc): A 3-arm phase III study (FIRSTANA). Oliver Sartor, MD Presented by Tony Choueiri, MD
16 Saturday 3 rd of September 2016 Abstract 5008: Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mcrpc) previously treated with docetaxel (D). Johann de Bono, MD Presented by Tony Choueiri, MD Abstract 5003: A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. Charles N. Catton, MD Presented by Elie Nasr, MD 15:45-16:30 Genitourinary (Nonprostate) Cancer Tony Choueiri, MD Abstract 4503: Limited versus extended pelvic lymphadenectomy in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial (LEA AUO AB 25/02). Juergen E. Gschwend, MD Presented by Tony Choueiri, MD Abstract 4506: Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC). Toni K. Choueiri, MD Presented by Tony Choueiri, MD Abstract LBA4500: Atezolizumab (atezo) as first-line (1L) therapy in cisplatinineligible locally advanced/metastatic urothelial carcinoma (muc): Primary analysis of IMvigor210 cohort 1. Arjun Vasant Balar, MD Presented by Tony Choueiri, MD 16:30 Adjourn 3:00-14:00 Lunch Break
17
18
Friday 2 nd of September 2016
Friday 2 nd of September 2016 08:00 Registration 09:00-10:00 Hematologic Malignancies - Lymphoma & Chronic Lymphocytic Leukemia Abstract 7501: A prospective, multicenter, randomized study of anti-ccr4
More informationContent. 头颈部肿瘤 (Head and Neck Cancer) 肺癌 (Lung Cancer) 摘要 页码
2016 年临床肿瘤学新进展学术研讨会 I 目 录 Content 头颈部肿瘤 (Head and Neck Cancer) 摘要 页码 A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly
More informationRoche Investor Relations ASCO Planner 2016
Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationSCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:
ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
More informationRoche Investor Relations ASCO Planner 2018
Roche Investor Relations ASCO Planner 2018 Friday, June 1 Session Title: Hematologic Malignancies Plasma Cell Dyscrasia Date: Fri, June 1 Time: 2:45 PM - 5:45 PM Speaker Name: Luciano J. Costa 3:57 PM
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationJuly 13-14, 2018 Phoenicia Hotel, Beirut - Lebanon
Organized by Lebanese Society of Medical Oncology Licensed by The American Society of Clinical Oncology www.lsmo-lb.org www.bestofasco.org 13 th Best of ASCO Lebanon July 13-14, 2018 - Phoenicia Hotel,
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationNCCN Guidelines for Central Nervous System Cancers V Follow-Up on 02/23/18
GLIO-3 and GLIO-4 Submission from Novocure Inc. (12/19/17 and 9/7/17) Please consider adding tumor treating fields in combination with temozolomide for the treatment of adult patients with newly diagnosed,
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationBest of ASCO. 66 September October 2016 OI
Best of ASCO 2016 66 www.accc-cancer.org September October 2016 OI BY CARY A. PRESANT, MD, FACP, FASCO THE 2016 ASCO ANNUAL MEETING WAS FILLED WITH INFORMATION, practice advice, and exciting results that
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationDevelopment status of OPDIVO (nivolumab) 1
May 12, 2017 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Non-small cell lung cancer (2 nd ~) Approved Approved Approved *) Non-small
More informationUniversity of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationJuly 13-14, 2018 Phoenicia Hotel, Beirut - Lebanon
Organized by Lebanese Society of Medical Oncology Licensed by The American Society of Clinical Oncology www.lsmo-lb.org www.bestofasco.org 13 th Best of ASCO Lebanon July 13-14, 2018 - Phoenicia Hotel,
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Décembre 2017 SEIN NEO ADJUVANT WO39392 (Impassion 031) : A phase III randomized study to investigate the efficacy and safety of Atezolizumab in combination
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of
More informationWASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationOPEN TRIALS Accruals counted until 30-April Current Accrual
Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine
More informationOpen Trials as of end of March 2016
EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationJuly 13-14, 2018 Phoenicia Hotel, Beirut - Lebanon
Under the Patronage of the President of the Lebanese Order of Physicians - Beirut Prof. Raymond Sayegh July 13-14, 2018 Phoenicia Hotel, Beirut - Lebanon Organized by The Lebanese Society of Medical Oncology
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationFor Health Professionals Who Care For Cancer Patients
April 2018 Volume 21, No. 4 For Health Professionals Who Care For Cancer Patients Inside This Issue: Editor s Choice New Programs: Palbociclib for Metastatic Breast Cancer, Adjuvant Capecitabine for Breast
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationScientific and Organizing Committee. LSMO Board. President of the Lebanese Society of Medical Oncology. Prof. Georges Chahine
Prof. Georges Chahine President of the Congress President of the Lebanese Society of Medical Oncology Scientific and Organizing Committee LSMO Board Dr. David Atallah Dr. Faysal El Kak Dr. Fadi Farhat
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT
PAGE 175 PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT Summary of risk management plan for pembrolizumab This is a summary of the risk management plan (RMP) for pembrolizumab. The RMP details
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationRoche Investor Relations ASCO Planner 2017
Roche Investor Relations ASCO Planner 2017 Saturday, June 3 Session Title: Lung Cancer Non-Small Cell Metastatic Date: Sat, June 3 Time: 8:00 AM 11:30 AM Speaker Name: Ibiayi Dagogo-Jack, MD; Yuichi Takiguchi,
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationRoche Investor Relations ASCO Planner 2015
Roche Investor Relations ASCO Planner 2015 Saturday, May 30 Session Title: Developmental Therapeutics Immunotherapy Poster Board: #341 Molecular, immune and histopathological characterization of NSCLC
More informationMedia Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Media Release Basel, 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 19 Roche medicines are included in
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationLudwig Presence at 2016 ASCO Annual Meeting
Ludwig Scientist(s) Affiliation(s) Session and Presentation Time Location Track Session Type/Title Presentation and/or Abstract Title Friday, June 3, 2016 Luisa Lina Villa Ludwig Sao Paulo 1:00pm - 3:15pm
More informationWelcome Committees Agenda Venue Registration
Welcome Committees Agenda Venue Registration Welcome On behalf of the Arab Medical Association Against Cancer (AMAAC) and the Lebanese Society of Medical Oncology (LSMO), it is with a great pleasure that
More informationThe Clinical Research E-News
Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal
More informationCancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 7: ISSUE 1: January 16, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
A031501 ALLIANCE NCT03244384 Bladder Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) Versus Observation NHLBI-MDS
More information14 th LEBANESE SOCIETY OF MEDICAL ONCOLOGY (LSMO) NATIONAL FORUM. March 30-31, April 1, Your Cancer Targeting with the right arrow
Your Cancer Targeting with the right arrow Target Cancer with the Right Arrow 14 th LEBANESE SOCIETY OF MEDICAL ONCOLOGY (LSMO) NATIONAL FORUM in collaboration with: March 30-31, April 1, 2017 PHOENICIA
More informationDevelopmental Therapeutics for HCC, Colorectal Cancer, and Pancreatic Cancer. Manish Sharma, MD Developmental Therapeutics Symposium April 20, 2018
Developmental Therapeutics for HCC, Colorectal Cancer, and Pancreatic Cancer Manish Sharma, MD Developmental Therapeutics Symposium April 20, 2018 Disclosure Information 23 rd Annual Developmental Therapeutics
More informationRoche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Media Release Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal combination
More informationNeoplasie uroteliali Posters & oral presentations
UPDATES and NEWS from the Genitourinary Cancers Symposium 3 Marzo 2017, Milano Neoplasie uroteliali Posters & oral presentations Cristina Masini Oncologia Medica IRCCS-Arcispedale S.Maria Nuova - Reggio
More information13th LEBANESE SOCIETY OF MEDICAL ONCOLOGY (LSMO) NATIONAL FORUM APRIL 7-9, 2016 HILTON HABTOOR HOTEL BEIRUT - LEBANON CAN CER BEAT
الجمعیة اللبنانیة للجراحة العامة CUBA BEAT in collaboration with: CAN CER 13th LEBANESE SOCIETY OF MEDICAL ONCOLOGY (LSMO) NATIONAL FORUM in collaboration with: APRIL 7-9, 2016 HILTON HABTOOR HOTEL BEIRUT
More informationStudienverzeichnis Medizinische Onkologie
Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationChemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
More informationThe Clinical Research E-News
Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationGeneral Overview of ASCO GI Alberto Zaniboni Oncologia Medica Fondazione Poliambulanza - Brescia
General Overview of ASCO GI 2018 Alberto Zaniboni Oncologia Medica Fondazione Poliambulanza - Brescia Le mie disclosures Research grants: Roche, Novartis, Pfizer, Astra Zeneca, Janssen, Boheringer Advisory
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationASCO 2018 Summary of Presentation. May 16, 2018
ASCO 2018 Summary of May 16, 2018 ASCO: Accepted s Oral presentations DS-8201 Pexidartinib Poster discussions U3-1402 Quizartinib DS-3032 Poster presentations Trial-in-Progress DS-8201 U3-1402 DS-1062
More informationDate of HRA. Date Site Invited. Date Site Selected. Approval. Recruited. Date
14/LO/0259 134883 RE-AKT: A randomised Phase II study of enzalutamide (MDV3100) in combination with AZD5363 in s with Metastatic Castration - Resistant Prostate Cancer Yes 08/01/2018 01/07/2016 01/07/2017
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 28 th Prioritization 3 rd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationThe Clinical Research E-News
Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized
More informationRoche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Investor Update Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 33 r d Prioritization 4 t h quarter 2017 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Please note: Within this document
More information